EFFET DE L'INOCULATION SUBSÉQUENTE DU VIRUS SV40 SUR LA TRANSPLANTATION DE CELLULES TRANSFORMÉES PAR CE VIRUS

1967 ◽  
Vol 13 (5) ◽  
pp. 543-549 ◽  
Author(s):  
R. Dubreuil ◽  
E. di Franco ◽  
V. Pavilanis ◽  
P. Marois

The inoculation of SV40 virus during the few days following the transplantation of SV40-transformed cells to adult hamsters inhibits the development of the transplanted tumors. The number and the size of the tumors are markedly reduced relative to those developing in control animals inoculated with medium 199.The animals that were resistant to the first transplantation, and those where the tumors were excised, showed an increased resistance to a second transplantation effected after an interval of 8 months.These results are interpreted as supporting the view that the transplantation of virus-transformed cells, and the development of the transplanted tumor, induce complex immunological reactions. The homologous oncogenic virus can be used to modify favorably the balance between cellular and humoral immune reactions conducive to the development of the tumor.

mBio ◽  
2017 ◽  
Vol 8 (4) ◽  
Author(s):  
Ying Zhu ◽  
Tingting Li ◽  
Suzane Ramos da Silva ◽  
Jae-Jin Lee ◽  
Chun Lu ◽  
...  

ABSTRACT While glutamine is a nonessential amino acid that can be synthesized from glucose, some cancer cells primarily depend on glutamine for their growth, proliferation, and survival. Numerous types of cancer also depend on asparagine for cell proliferation. The underlying mechanisms of the glutamine and asparagine requirement in cancer cells in different contexts remain unclear. In this study, we show that the oncogenic virus Kaposi’s sarcoma-associated herpesvirus (KSHV) accelerates the glutamine metabolism of glucose-independent proliferation of cancer cells by upregulating the expression of numerous critical enzymes, including glutaminase 2 (GLS2), glutamate dehydrogenase 1 (GLUD1), and glutamic-oxaloacetic transaminase 2 (GOT2), to support cell proliferation. Surprisingly, cell crisis is rescued only completely by supplementation with asparagine but minimally by supplementation with α-ketoglutarate, aspartate, or glutamate upon glutamine deprivation, implying an essential role of γ-nitrogen in glutamine and asparagine for cell proliferation. Specifically, glutamine and asparagine provide the critical γ-nitrogen for purine and pyrimidine biosynthesis, as knockdown of four rate-limiting enzymes in the pathways, including carbamoylphosphate synthetase 2 (CAD), phosphoribosyl pyrophosphate amidotransferase (PPAT), and phosphoribosyl pyrophosphate synthetases 1 and 2 (PRPS1 and PRPS2, respectively), suppresses cell proliferation. These findings indicate that glutamine and asparagine are shunted to the biosynthesis of nucleotides and nonessential amino acids from the tricarboxylic acid (TCA) cycle to support the anabolic proliferation of KSHV-transformed cells. Our results illustrate a novel mechanism by which an oncogenic virus hijacks a metabolic pathway for cell proliferation and imply potential therapeutic applications in specific types of cancer that depend on this pathway. IMPORTANCE We have previously found that Kaposi’s sarcoma-associated herpesvirus (KSHV) can efficiently infect and transform primary mesenchymal stem cells; however, the metabolic pathways supporting the anabolic proliferation of KSHV-transformed cells remain unknown. Glutamine and asparagine are essential for supporting the growth, proliferation, and survival of some cancer cells. In this study, we have found that KSHV accelerates glutamine metabolism by upregulating numerous critical metabolic enzymes. Unlike most cancer cells that primarily utilize glutamine and asparagine to replenish the TCA cycle, KSHV-transformed cells depend on glutamine and asparagine for providing γ-nitrogen for purine and pyrimidine biosynthesis. We identified four rate-limiting enzymes in this pathway that are essential for the proliferation of KSHV-transformed cells. Our results demonstrate a novel mechanism by which an oncogenic virus hijacks a metabolic pathway for cell proliferation and imply potential therapeutic applications in specific types of cancer that depend on this pathway.


1983 ◽  
Vol 35 (2) ◽  
pp. 144-149 ◽  
Author(s):  
KOJU KAMATA ◽  
MICHIHITO OKUBO ◽  
EIKO ISHIGAMORI ◽  
YOSHIHIKO MASAKI ◽  
HISANORI UCHIDA ◽  
...  

Blood ◽  
2009 ◽  
Vol 113 (11) ◽  
pp. 2461-2469 ◽  
Author(s):  
Henrik E. Mei ◽  
Taketoshi Yoshida ◽  
Wondossen Sime ◽  
Falk Hiepe ◽  
Kathi Thiele ◽  
...  

AbstractProviding humoral immunity, antibody-secreting plasma cells and their immediate precursors, the plasmablasts, are generated in systemic and mucosal immune reactions. Despite their key role in maintaining immunity and immunopathology, little is known about their homeostasis. Here we show that plasmablasts and plasma cells are always detectable in human blood at low frequency in any unimmunized donor. In this steady state, 80% of plasmablasts and plasma cells express immunoglobulin A (IgA). Expression of a functional mucosal chemokine receptor, C-C motif receptor 10 (CCR10) and the adhesion molecule β7 integrin suggests that these cells come from mucosal immune reactions and can return to mucosal tissue. These blood-borne, CCR10+ plasmablasts also are attracted by CXCL12. Approximately 40% of plasma cells in human bone marrow are IgA+, nonmigratory, and express β7 integrin and CCR10, suggesting a substantial contribution of mucosal plasma cells to bone marrow resident, long-lived plasma cells. Six to 8 days after parenteral tetanus/diphtheria vaccination, intracellular IgG+ cells appear in blood, both CD62L+, β7 integrin−, dividing, vaccine-specific, migratory plasmablasts and nondividing, nonmigratory, CD62L− plasma cells of different specificities. Systemic vaccination does not impact on peripheral IgA+ plasmablast numbers, indicating that mucosal and systemic humoral immune responses are regulated independent of each other.


1967 ◽  
Vol 13 (11) ◽  
pp. 1433-1444 ◽  
Author(s):  
R. Dubreuil ◽  
E. Di Franco ◽  
V. Pavilanis ◽  
P. Marois

The induction and the growth of viral SV 40 tumors in hamsters can be influenced by treating the animals with the oncogenic virus itself. The virus can be used to vaccinate against the transplanted tumor cells; it can also be used as a treatment to prevent the development of the tumor after its induction in the newborn by the virus or in the adult by the implantation of tumor cells.The present study reports that the administration of SV 40 virus to adult hamsters immediately following the excision of their transplanted SV 40 tumor brings a reduction in the frequency of recurrences appearing after the operation. It was also observed that among the animals that did not present recurrences after 7 to 10 months, those that were treated with the virus at the time of the surgical intervention, were still more resistant to the reimplantation of homologous cancer cells.These observations are interpreted as another indication that the evolution of a tumor can be modified in a favorable way by immunological means, in this instance, by a treatment with the oncogenic virus itself.


2006 ◽  
Vol 177 (7) ◽  
pp. 4907-4916 ◽  
Author(s):  
Zeyu Xiong ◽  
Enli Liu ◽  
Yan Yan ◽  
Richard T. Silver ◽  
Fan Yang ◽  
...  

2007 ◽  
Vol 122 (3) ◽  
pp. 279-287 ◽  
Author(s):  
Zeyu Xiong ◽  
Yan Yan ◽  
Enli Liu ◽  
Richard T. Silver ◽  
Srdan Verstovsek ◽  
...  

2000 ◽  
Vol 35 (4) ◽  
pp. 667-673 ◽  
Author(s):  
Georg A. Böhmig ◽  
Heinz Regele ◽  
Marcus D. Säemann ◽  
Markus Exner ◽  
Wilfred Druml ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document